Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Issue title: Novel Approaches to Alzheimer's Disease Therapeutics
Guest editors: Muhammad Omar Chohan
Article type: Research Article
Authors: Sigurdsson, Einar M.; *
Affiliations: Departments of Physiology and Neuroscience, and Psychiatry, New York University School of Medicine, New York, NY, USA
Correspondence: [*] Address for correspondence: Einar M. Sigurdsson, Ph.D., Departments of Physiology and Neuroscience, and Psychiatry, New York University School of Medicine, Millhauser Labs. Room HN418, 560 First Avenue, New York, NY 10016, USA. Tel.: +1 212 263 3913; Fax: +1 212 263 6751; E-mail: einar.sigurdsson@med.nyu.edu.
Abstract: Immunotherapies that target the amyloid-β (Aβ) peptide in Alzheimer's disease (AD) have shown promise in animal and human studies. Although the first clinical trial was halted because of adverse reactions, this approach has been refined and additional trials are underway. Another important target in AD is the neurofibrillary tangles, composed primarily of hyperphosphorylated tau proteins, which correlate well with the degree of dementia. As Aβ and tau pathologies are likely synergistic, targeting both should be more effective and may be essential as early diagnosis prior to cognitive decline is currently not available. Also, Aβ immunotherapy only results in a very limited indirect clearance of tau aggregates in dystrophic neurites, showing the importance of developing a separate therapy that directly targets pathological tau. Our findings in two tangle mouse models indicate that immunization with a phospho-tau derivative reduces aggregated tau in the brain and slows progression of the tangle-related behavioral phenotype. These antibodies enter the brain and bind to pathological tau within neurons. We are currently clarifying further the mechanism of action of this promising therapeutic approach and determining its epitope specificity.
Keywords: Amyloid-β, immunization, immunotherapy, tau, vaccine
DOI: 10.3233/JAD-2008-15202
Journal: Journal of Alzheimer's Disease, vol. 15, no. 2, pp. 157-168, 2008
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl